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Abstract
Background: Hepatocellular carcinoma (HCC) is highly malignant and metastatic. Currently, there is no effective
chemotherapy for patients with advanced HCC leading to an urgent need to seek for novel therapeutic options. We aimed
to investigate the effect of a garlic derivative, S-allylcysteine (SAC), on the proliferation and metastasis of HCC.
Methodology/Principal Findings: A series of in vitro experiments including MTT, colony-forming, wound-healing,
invasion, apoptosis and cell cycle assays were performed to examine the anti-proliferative and anti-metastatic effects of
SAC on a metastatic HCC cell line MHCC97L. The therapeutic values of SAC single and combined with cisplatin
treatments were examined in an in vivo orthotopic xenograft liver tumor model. The result showed that the
proliferation rate and colony-forming abilities of MHCC97L cells were suppressed by SAC together with significant
suppression of the expressions of proliferation markers, Ki-67 and proliferating cell nuclear antigen (PCNA). Moreover,
SAC hindered the migration and invasion of MHCC97L cells corresponding with up-regulation of E-cadherin and down-
regulation of VEGF. Furthermore, SAC significantly induced apoptosis and necrosis of MHCC97L cells through
suppressing Bcl-xL and Bcl-2 as well as activating caspase-3 and caspase-9. In addition, SAC could significantly induce
the S phase arrest of MHCC97L cells together with down-regulation of cdc25c, cdc2 and cyclin B1. In vivo xenograft liver
tumor model demonstrated that SAC single or combined with cisplatin treatment inhibited the progression and
metastasis of HCC tumor.
Conclusions/Significance: Our data demonstrate the anti-proliferative and anti-metastatic effects of SAC on HCC cells and
suggest that SAC may be a potential therapeutic agent for the treatment of HCC patients.
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Introduction
Hepatocellular carcinoma (HCC) is one of the most life-
threatening cancers causing more than half million incidences and
deaths per year in the world [1]. Treatment options are greatly
limited for patients with advanced HCC due to presence of large
size tumors and potential metastasis [2]. Badly, there is no effective
systemic chemotherapy for advanced HCC patients. Therefore the
development of novel treatment regimens is a pressing need for
these patients.
Garlic, a member of Allium vegetables, has been applied for
medicinal uses a long time ago [3]. Allium vegetables derived
organosulfur compounds (OSCs) have been found to be potentially
preventive and therapeutic agents against cancers [4,5,6]. There
are two major types of OSCs extracted from garlic: one is lipid
soluble type such as diallyl sulfide (DAS), diallyl disulfide (DADS),
diallyl trisulfide (DATS) and dithiins, another is water soluble type
including S-allylcysteine (SAC) and S-allylmercaptocysteine
(SAMC) [6]. Several lines of evidences have proved that SAC is
an anti-tumor agent against different human cancers such as
prostate cancer [7,8], breast cancer [9], oral cancer [10],
neuroblastoma [11] and non-small-cell lung carcinoma [12].
Moreover, the applications of SAC for in vivo treatment of cancers
showed no signed toxicity on the nude mice [8]. The major effects
of SAC against tumors include induction of apoptosis, inhibition of
proliferation and suppression of invasion and adhesion
[4,6,9,10,13]. A recent study indicated that SAC can prevent N-
nitrosodiethylamine (NDEA)-induced hepatocarcinogenesis in
Wistar rats [14]. Up to now the effect of SAC on treating human
HCC has not been studied. We aimed to investigate the potential
of SAC in suppressing the proliferation and metastasis of human
HCC cells through a series of in vitro and in vivo experiments. The
molecular mechanisms of SAC-induced effects on HCC cells and
the possibility of combining SAC with traditional chemotherapy to
treat HCC cells were also investigated.
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Materials and Methods
S-allylcysteine (SAC)
SAC was provided by Wakunaga Pharmaceutical Co., Ltd.
(Hiroshima, Japan). A stock solution of SAC (100 mM) was
prepared freshly in phosphate-buffering saline (PBS) according to
the instruction.
Cell lines
A human metastatic HCC cell line, MHCC97L, was provided
by Liver Cancer Institute & Zhongshan Hospital of Fudan
University, Shanghai, China [15]. The cell line was cultured in
DMEM high glucose medium (Gibco) with 10% fetal bovine
serum (FBS, Gibco) and 1% penicillin and streptomycin in a 37uC
incubator supplied with 5% CO2. Luciferase gene integrated
MHCC97L cells [16], named MHCC97L-Luc, were used for in
vivo experiment.
MTT assay
Three thousand cells per well were seeded in 96-well plates and
incubated in normal condition for 24 hours. Cells were treated
with different concentrations of SAC for 2, 3 and 4 days. Cells
were treated with 100 ml of 5 mg/ml of (3-(4,5-Dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT, Invitrogen) solution
for 3 hours at 37uC until crystals were formed. MTT solution was
removed from each well and 100 ml of DMSO was added to each
well to dissolve the formed crystals. Color intensity was measured
by Microplate Reader (Model 680, Bio-Rad) at 570 nm. Each
experiment consisted of four replications and at least three
individual experiments were carried out.
Colony-forming assay
Cells of single-cell suspension (500 cells per well) were
inoculated in 6-well plates and incubated for 24 hours. The cells
were treated with different concentrations of SAC for 2 weeks.
The cells were fixed by ice-cold methanol and stained by Crystal
violet for 10 minutes. Colonies (more than 50 cells) were counted
directly on the plate. Statistical significant was calculated from
each four independent experiments.
Wound-healing assay
Cells were seeded onto 24-well plates and incubated for
24 hours to reach 100 percent confluence of the well. A straight-
line-wound was made by scraping a 20 ml-pipette tip across the cell
monolayer. Cells were rinsed with PBS and cultured with 0 mM,
20 mM and 40 mM of SAC for 48 hours. The wound was
captured at 0, 24 and 48 hour under microscopy.
Invasion assay
Invasion assay was performed by using BD BioCoatTM BD
MatrigelTM Invasion Chamber (BD Biosciences). Briefly, 56104
cells were suspended in 500 ml of serum-free DMEM and seeded
into the migration chamber. The migration chamber was placed
into a 24-well plate with 500 ml of 0 mM, 20 mM or 40 mM of
SAC. After 24 hours of incubation, cells on the upper surface of
the chamber were scrapped out by a cotton swab. Cells migrated
through the chamber were stained by hematoxylin and eosin (H &
E) and subsequently counted under the microscope. At least three
independent experiments were performed.
Apoptosis assay
Cells (36105) were seeded onto 6-well plate for 24 hours. The
cells then were treated with different concentrations of SAC
ranging from 0 mM to 40 mM for 2 days. The cells were
harvested and stained with Annexin-V-Fluor Staining Kit (Roche)
according to manufactory’s instruction and analysis by flow
cytometer. Early apoptosis was defined as Annexin V-positive
and PI-negative cells. Late apoptosis was defined as Annexin V-
positive and PI-positive cells. Necrosis was defined as Annexin V-
negative and PI-positive cells. Each experiment was analysed in
triplicate and at least three independent experiments were
performed.
Cell cycle analysis
Cells (36105) were seeded onto 6-well plate for 24 hours. The
cells were treated with different concentrations of SAC ranging
from 0 mM to 40 mM for 24 hours. The cells were trypsinized
and fixed with 75% ice-cold ethanol for one hour and stained with
1 mg/ml of propidium iodide (PI) and 0.5 mg/ml of RNase A at
37uC for 30 minutes. DNA content of 10,000 cells from each
experiment was analyzed by flow cytometer. Each experiment was
analysed in duplicate and four independent experiments were
performed.
Quantitative real-time RT-PCR
The quantitative real-time RT-PCR analysis was conducted as
previously described [17]. Briefly, Total RNAs from cells were
isolated by TRIZol regent (Invitrogen). cDNA was synthesized by
High capacity cDNA Kit (Applied Biosystems). Each of the target
genes was amplified by using Power SYBR Green PCR Master
Mix (Applied Biosystems) and analyzed by a 7700 Sequence
Detection Instrument (Applied Biosystems). Threshold cycle (Ct)
value for each sample was determined by the preset parameters of
the instrument. Dissociation curve was examined for every PCR
reaction to ensure a specific PCR product. Quantitative RT-PCR
was performed in triplicates and repeated three times. Primers
used including 18S sense 59-CTCTTAGCTGAGTGTCCCGC-
39; anti-sense 59-CTGATCGTCTTCGAACCTCC-39; prolifer-
ating cell nuclear antigen (PCNA) sense 59-GGCTCCATCCT-
CAAGAAGGT-39, antisense 59-CAAAGAGACGTGGGACGA-
GT-39; E-cadherin sense 59-GAACGCATTGCCACATACAC-
39; anti-sense 59-ATTCGGGCTTGTTGTCATTC-39; vascular
endothelial growth factor (VEGF) sense 59-CGAAGTGGT-
GAAGTTCATGGATG-39, anti-sense 59-TTCTGTATCAGTC-
TTTCCTGGT-39.
Western blot
Proteins were extracted by 16 Lysis Buffer (Cell Signaling).
Protein extracts were separated by 12% SDS-PAGE and
transferred to PDMF membrane (Millipore). After blocking with
5% non-fat milk for 1 hour, primary antibody in appropriately
dilution was hybridised with the membrane at 4uC over night. The
membrane was washed 3 times with TBS/T each for 10 minutes
and incubated with secondary antibody for 1 hour at room
temperature. Protein signal was detected by ECL Plus system (GE
Healthcare). Antibodies used including PCNA, VEGF (Santa
Cruz), Caspase-3 (Cell signalling), Cleaved caspase-3 (Cell
signalling), Caspase-9 (Cell signalling), Cleaved caspase-9 (Cell
signalling), Bcl-2 (Cell signalling), Bcl-xL (Cell signalling), Actin
(Santa Cruz), cdc25 (Cell signalling), cdc2 (Cell signalling) and
cyclin B1 (Cell signalling).
Immunofluorescence staining
Cells (36105) were seeded onto 6-well plate for 24 hours. The
cells were treated with different concentrations of SAC ranging
from 0 mM to 40 mM for 24 hours. The cells were harvested and
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fixed with 4% paraformaldehyde at 4uC for 15 min. After
washing, the fixed cells were permeabilized by incubated with
0.2% triton X-100 in PBS for 10 min at room temperature. The
cells were blocked with 5% BSA for 30 min. The cells were
incubated with Ki-67 antibody (BD Biosciences) for 30 min at
room temperature. After washing, FITC-conjugated secondary
antibody (Santa Cruz) was incubated with the cells for 30 min at
room temperature. The labeled cells were analyzed by flow
cytometer. Three replicates were performed.
Orthotopic xenograft nude mice liver tumor model
Male athymic nude mice (BALB/c nu/nu, 4–6 weeks old) were
used. The mice were housed in a standard animal laboratory
under constant environment conditions with a 12-h light and dark
cycle with water and chow. They were kept MHCC97L-luc cells
(16106) in 0.1 ml culture medium were injected subcutaneously
into a nude mouse. Once the subcutaneous tumor reached 0.8 to
1 cm in diameter, it was cut into cubes (,1 to 2 mm3 in size) and
then implanted into the left liver lobes of nude mice [18]. The
treatment started 1-week after the implantation. The mice were
divided into three groups: Control (PBS), SAC (1 mg SAC/kg/
day) and SAC plus Cisplatin (1 mg SAC/kg/day plus 1 mg
cisplatin/kg/day). Xenogen IVISH in vivo imaging system was used
to monitor the growth of liver tumor and lung metastasis. The
mice were sacrificed at 6-weeks after implantation. Animal studies
had been specifically approved by Animal (Control of Exper-
iments) Ordinance Chapter 340, the Department of Health, Hong
Kong Special Administrative Region (Ref.: (09–737) in DH/
HA&P/8/2/3 Pt. 17).
Statistical analysis
Statistical analysis was carried out using SPSS 16.0 for Windows
(SPSS Inc., IL). For category variables, Chi-square test with
Fisher’s extract was used. Two-tailed Student’s t-test was used for
analysis of continuous variables. P,0.05 was considered to be
statistically significant.
Results
SAC suppresses proliferation of HCC cells
To investigate the effect of SAC on the growth of HCC cells,
MTT and colony-forming assays were performed. MTT assay
demonstrated that SAC suppressed the proliferation of
MHCC97L cells in time- and dose-dependent manners
(Figure 1A). The highest concentration of SAC did not reach
the half maximal inhibitory concentration (IC50) to MHCC97L
cells at day 2. SAC exhibited an increasing suppressive effect on
MHCC97L cells after 3 days of treatment. The IC50 of SAC to
Figure 1. The effect of SAC on proliferation and colony-forming ability of MHCC97L cells. (A) MTT assay at day 2, 3 and 4. (B)
Representative plates of colony-forming assay (C) Bar-chart of colony-forming assay. Statistical analysis was performed by comparing to the value of
0 mM SAC treatment. **, p,0.01.
doi:10.1371/journal.pone.0031655.g001
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MHCC97L cells was about 33 mM and 22 mM at day 3 and day
4 respectively. Moreover, colony-forming ability of MHCC97L
cells was significantly inhibited by SAC treatment with concen-
trations from 5 mM to 40 mM (Figure 1B and 1C). There was no
colony formed in 40 mM of SAC. To elucidate the anti-
proliferative mechanism of SAC on MHCC97L cells, the
expressions of two proliferative markers, Ki-67 and PCNA, were
examined. The study of immunofluorescent staining of Ki-67
antibody showed that the number of Ki-67 stained MHCC97L
cells was significantly reduced after treatment with 20 mM and
40 mM of SAC for 48 hours (Fig. 2A and 2B). There was a more
than 4-folds down-regulation of Ki-67 expression in MHCC97L
cells after 40 mM SAC treatment compared with the cells without
SAC treatment (6.3% vs 25.0%, Fig. 2B). Additionally, the
expressions of PCNA mRNA and protein were significantly down-
regulated after 48-hour SAC treatment in a dose-dependent
manner (Fig. 2C and 2D).
SAC induces apoptosis of HCC cells
Anti-apoptosis is one of the important mechanisms that HCC
cells utilize it to protect themselves from chemotherapies. To
investigate whether SAC affects apoptosis in HCC cells, Annexin
V and PI staining was performed. The result of apoptosis assay
demonstrated that the percentages of the early apoptotic, late
apoptotic and necrotic cells of MHCC97L cells were significantly
increased after treatments with SAC for 48 hours in a dose-
dependent manner (Fig. 3A and 3B). Among them, late apoptosis
was the most influenced one by SAC. There were 3.5-, 5.2- and
2.8-fold increases of early apoptosis, late apoptosis and necrosis of
MHCC97L cells respectively at 40 mM SAC treatment compared
with the cells without treatment (Fig. 3B). By combining the
percentages of early and late apoptotic cells, SAC treatment at
40 mM caused a 4.5-fold increase of the total percentage of
apoptotic cells compared to the cells without treatment. Western
blot analysis showed that cleaved caspase-3 and cleaved caspase-9
of MHCC97L cells were activated along with SAC treatment and
both reached the highest level at 40 mM of SAC (Fig. 3C). The
protein level of caspase-9 was increased along with SAC treatment
while the protein level of caspase-3 was decreased (Fig. 3C).
Moreover, the expressions of anti-apoptotic proteins Bcl-xL and
Bcl-2 in MHCC97L cells were suppressed by SAC treatment
(Fig. 3C). The suppressive effect of SAC on Bcl-xL was found to be
a dose-dependent manner and was more obvious than on Bcl-2
(Fig. 3C).
SAC arrests S phase of HCC cells
To investigate the effect of SAC on cell cycle of HCC, DNA
content of MHCC97L cells was analyzed by PI staining. Our result
showed that SAC treatment resulted in a significant increase of S
phase content of MHCC97L cells (Fig. 4A and 4B). The content of
S phase of MHCC97L cells was increased to more than 36% after
#20 mM of SAC was administrated while the content of S phase of
the cells without treatment was 24% (Fig. 4B). The significant arrest
in S phase caused a significant decrease of G2/M phase content
Figure 2. The effect of SAC on the expressions of Ki-67 and PCNA of MHCC97L cells. (A) Representative immunofluorescent analysis of Ki-
67 protein after SAC treatment for 48 hours. X-axis represents Ki-67 intensity and Y-axis represents cell number. (B) Bar-chart of immunofluorescent
analysis of Ki67 protein under SAC treatment. (C) Quantitative real-time RT-PCR and (D) Western blot analyses of PCNA mRNA and protein
respectively after SAC treatment for 48 hours. Statistical analysis was performed by comparing to the value of 0 mM SAC treatment. **, P,0.01.
doi:10.1371/journal.pone.0031655.g002
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(Fig. 4B). There was no significant change of G1 phase between
SAC treated and non-treated MHCC97L cells (Fig. 4B). Western
blot analysis showed that the expressions of cdc25c, cdc2 and cyclin
B1 proteins in MHCC97L cells were suppressed after SAC
treatment in a dose-dependent manner (Fig. 4C).
SAC suppresses migration and invasion of HCC cells
To further investigate the anti-metastatic property of SAC on
HCC cells, wound healing assay and invasion assay were
performed to study the changes of in vitro migration and invasion
abilities of MHCC97L cells under SAC treatment. Wound-healing
assay demonstrated that the migration ability of MHCC97L cells
after creation of the wound was hindered by treatment of 40 mM
SAC compared to the cells without SAC treatment (Fig. 5A).
Moreover, administration of SAC at the concentration of 20 mM
and 40 mM significantly inhibited the invasion ability of
MHCC97L (Fig. 5B). To understand the molecular mechanism
of the effect of SAC on the metastatic ability of HCC cells, the
expressions of two important metastasis-related genes including E-
cadherin and VEGF were analyzed by quantitative real-time RT-
PCR. Significant and dose-dependent up-regulation of E-cadherin
mRNA (Fig. 5C) and down-regulation of VEGF mRNA (Fig. 3D)
were detected in MHCC97L cells after treatment of SAC.
SAC suppresses in vivo growth and metastasis of HCC cells
Single SAC treatment and SAC combined with cisplatin
treatment significantly reduced the in vivo tumor volume of
MHCC97L-Luc cells to approximately 4 and 6 folds respectively
(Fig. 6A, 6B and Table 1). There was no significantly difference
between single and combination treatment on suppressing tumor
growth (Table 1). The lung metastatic potential of MHCC97L-
Luc was suppressed by SAC single or combined with cisplatin
treatment (Fig. 6C). Single SAC treatment reduced the lung
metastatic rate of MHCC97L cells from 87.5% to 37.5%, but
there was no statistical significance between single SAC treatment
group and control group (Table 1). SAC combined with cisplatin
significantly reduced the lung metastatic rate of MHCC97L-Luc
cells to 12.5% compared to the control group (Table 1). There was
no statistically significant difference between single and combina-
tion treatments in suppressing lung metastasis of HCC cells
(Table 1).
Discussion
Surgical treatments such as liver resection and liver transplan-
tation provide better clinical outcome for patients with early stage
of HCC. Up to 70% of HCC patients have been suffering from
limited treatment options due to late diagnosis and/or advanced
stage of the disease when however, surgical treatments as well as
regional therapy are not feasible. So far, targeted therapy is no
even satisfactory for advanced HCC patients [2]. Therefore, we
aimed to seek for alternative regimens which can effectively
eradicate the progression and metastasis of HCC. SAC, a garlic
derived water soluble organosulfur compound (OSC), has been
Figure 3. The effect of SAC of apoptosis of MHCC97L cells. (A) Flow cytometry analysis of MHCC97L cells. X-axis represents Annexin V label
and Y-axis represents PI label. (B) Summary of apoptosis assay. (C) Western blot analysis of apoptosis proteins under SAC treatment. Statistical analysis
was performed by comparing to the value of 0 mM SAC treatment. *, p,0.05; **, P,0.01.
doi:10.1371/journal.pone.0031655.g003
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demonstrated to have anti-tumor effects in different human
cancers [7,9,10,11,12,13]. With no previous report of SAC in
the treatment of human HCC, we employed a series of in vitro and
in vivo functional studies to investigate the anti-proliferative and
anti-metastatic effects of this agent on a human metastatic HCC
cell line.
In this study, we demonstrated that SAC could inhibit the
proliferation rate of MHCC97L cells in dose- and time-dependent
manners. The anti-proliferative effect of SAC on MHCC97L cells
was more notable after more than 3 days of treatment. These
phenomena were comparable to the effect of SAC on other
cancers such as breast, prostate and lung cancers [7,9,12],
suggesting a common effective action time of SAC on cancers.
Moreover, SAC significantly inhibited the colony-forming ability
of HCC97L cells from single cell, indicating its suppressive effect
on HCC initiation. Furthermore, the animal study demonstrated
that administration of SAC significantly inhibited the in vivo
growth of MHCC97L-Luc cells. The anti-proliferative effect of
SAC on MHCC97L cells was explained to be its suppressive effect
on the expressions of proliferative markers including Ki-67 and
PCNA. High label index of PCNA has been found to be
significantly associated with larger tumor size, high recurrence
rate and poor survival outcome of HCC patients after hepatec-
tomy [19]. The anti-proliferative effect of SAC on HCC cells
through suppression of PCNA indicates it possible therapeutic
application for treatment of HCC patients.
Evasion of apoptosis is one of the hallmarks of cancers [20].
Members of Allium vegetable-derived OSCs have been found to
suppress the growth of cancers through induction of apoptosis of
tumor cells [5,6]. Currently, the effect of SAC on apoptosis of
cancers has been elusive. In human prostate cancer, SAC can
elevate apoptosis of the cancer cells under in vivo environment
through activation of cleaved caspase-3 and down-regulation of
Bcl-2 [8]. In this study, we found that SAC could significantly
induce apoptosis and necrosis of HCC cells in a dose-dependent
manner. Moreover, SAC treatment on HCC cells could lead to
activations of cleaved caspase-3 and cleaved caspase-9 as well as
down-regulation of Bcl-xL and Bcl-2 expressions. Bcl-xL and Bcl-2
which have anti-apoptotic function by protecting mitochondria
from cytochrome c release are commonly over-expressed in
cancers [20]. Therefore, these results suggested that the suppres-
sive effect of SAC of HCC cells might be attributed to the
induction of caspase-mediated apoptosis through down-regulation
of anti-apoptotic proteins.
Several lines of evidences suggest that cancer cells treated with
OSCs can lead to the arrest in G2/M phase of the cell cycle
through modulating the expressions or activities of cyclins, cyclin-
dependent kinases (Cdks) , signaling molecules and histones [6]. A
study showed that SAMC but not SAC inhibits the growth of
human colon cancer cell lines at G2/M phase of the cell cycle
[21]. In this study, we demonstrated, for the first time, that SAC
caused a significant accumulation of MHCC97L cells at S phase
resulting in significantly decreased number of cells at G2/M phase
of the cell cycle, suggesting that SAC might suppress the
proliferation of HCC cells by inducing cell cycle at S/G2
transition. Inhibition of cdc25c, cdc2 and cyclin B1 is associated
with the delays of S phase progression of HCC cells after
interferon-a treatment [22]. Our result showed that the expres-
Figure 4. The effect of SAC of cell cycle of MHCC97L cells. (A) Representative histograms of cell cycle analysis. Y-axis represent number of cells;
X-axis represents DNA content (PI intensity). (B) Distribution of G2, S and G1 phases of MHCC97L cells under SAC treatment. (C) Western blot analysis
of S phase regulated proteins. Statistical analysis was performed by comparing to the value of 0 mM SAC treatment. *, p,0.05; **, P,0.01.
doi:10.1371/journal.pone.0031655.g004
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sions of cdc25c, cdc2 and cyclin B1 in HCC cells were down-
regulated by SAC treatment in a dose-dependent manner,
indicating SAC may delay S phase progression to G2/M phase
of HCC cells through suppression of cell cycle regulators.
Moreover, cdc25c, cdc2 and cyclin B1 are important regulators
in controlling G2/M transition of the cell cycle [23]. Arrest in G2/
M phase of cancer cells by other OSCs, such as DADS, DAS and
DATS, has been found to be associated with down-regulation of
cdc25c proteins [6,24]. Thus, down-regulation of cdc25c, cdc2
and cyclin B1 by SAC might also suggest the influence of SAC on
G2/M transition of HCC cells. Cdc2 and cyclin B1 are commonly
overexpressed in HCC patients and the overexpressions of these
Figure 5. The effect of SAC on migration and invasion of MHCC97L cells. (A) Wound-healing assay of MHCC97L cells under SAC treatment.
(B)Invasion assay. Quantitative real-time RT-PCR analyses of (C) E-cadherin and (D) VEGF mRNA. Statistical analysis was performed by comparing to
the value of 0 mM SAC treatment. *, p,0.05; **, P,0.01.
doi:10.1371/journal.pone.0031655.g005
Figure 6. The Effect of SAC of in vivo tumor growth and metastasis of MHCC97L cells. (A) In vivo images of rats by Xenogen IVISH imaging
system at week 6 after implantation. (B) Tumor-bearing liver tissues (C) In vivo images of lung tissues by Xenogen IVISH imaging system.
doi:10.1371/journal.pone.0031655.g006
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genes are positively associated with higher malignant status and
poor prognosis of HCC patients [25,26]. Suppression of cdc2 and
cyclin B1 expressions by SAC might suggest the therapeutic
implication of SAC for the treatment of HCC patients.
Patients with advanced or metastatic HCC only rely on systemic
chemotherapy which cannot achieve improved overall survival for
these patients [2,27]. Apart from anti-proliferative effect on
cancers, SAC has been found to inhibit the invasion of cancer
cells such as breast and prostate cancer cells by modulating the
expression of E-cadherin [7,9]. Therefore, the effect of SAC on
HCC metastasis was also investigated in this study. MHCC97L is
a metastatic cell line which can metastasize to the lung from the
liver [16,28]. Our in vitro study demonstrated that SAC effectively
suppressed the migration and invasion abilities of MHCC97L
cells. Furthermore, in vivo study showed that SAC could reduce the
metastatic potential of MHCC97L-Luc cells from 87.5% to
37.5%, suggesting an anti-metastatic effect of SAC on HCC
metastasis. Moreover, combination of SAC and cisplatin could
significantly inhibit lung metastasis of MHCC97L-luc cells,
indicating its synergetic implication on HCC treatment. Metastasis
is a multi-step process which is composed of invasion, intravasion,
arrest in bloodstream, extravasion and metastatic colonization
[29]. E-cadherin and VEGF are two important regulators of
cancer metastasis [29]. The decrease or loss of E-cadherin has
been frequently found in tumor tissues of HCC patients which is
significantly associated with advanced HCC stages and high
recurrent rate after liver resection [30]. Up-regulation of E-
cadherin by TGF-beta inhibitor can hinder the epithelial-
mesenchymal transition (EMT) process of HCC cells resulting in
suppression of migration and invasion [31]. VEGF is a critical
factor of angiogenesis whose up-regulation in HCC patients is
significantly associated with high proliferative index, angiogenesis,
tumor invasion and poor prognosis after liver resection [32].
Targeted inhibition of VEGF has been proved to improve clinical
outcome of advanced HCC patients [33]. In this study, SAC could
restore the expression of E-cadherin and suppress the expression of
VEGF of MHCC97L cells, suggesting its anti-metastatic effect on
HCC through inhibition of HCC invasion and angiogenesis.
In summary, our data demonstrated that SAC could suppress
the proliferation and metastatic potential of HCC by modulating
important regulators involved in proliferation, invasion, apoptosis,
cell cycle and angiogenesis, suggesting that SAC may be a
potential therapeutic agent for the treatment of HCC patients.
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